The supplement to this issue of the Ear, Nose & Throat Journal , on antibiotic resistance in otitis media, should be of interest to all otolaryngologists with a serious interest in otitis media. Furthermore, by extrapolation, it is also both important and relevant with respect to sinusitis. The past one to two years marked a turning point in the history of the use of antimicrobials for otitis media. First, changes in antibiotic susceptibility (particularly among Streptococcu s pneumoniaei have rendered many of our antimicrobials substantially less effective than in years past. Second, several lines of in vitro and in vivo data all lead to the same conclusions about the relative efficacy of various agents. The availability and the relative consistency of the data is the good news ; the bad news is in the message carried.
The work being conducted by Professor Ron Dagan and his colleagues in Israel is, in my opinion, the single most important line of clinical investigations ever performed concerning antibiotic therapy for respiratory infections. The trials are difficult to carry out, but the results are unambiguous and consistent, and the group's reporting of the data over the'past few years has been straightforward and apparently unbiased. The team has multiple manuscript s, reflecting volumes of pertinent data in various degrees of preparation, and I would highly recommend their work as worthy of our attention. Dagan's efforts have been in children. Also in the supplement, Dr. Craig's model of predicting effectiveness is probably the most commonly cited pharmacodynamic measurement in otitis media : the percent of the dosing interv al producing a serum level above the minimum inhibitory concentration (MIC). Related to that is another measurement only briefly mentioned in the supplement, the ratio of peak serum level to MIC. To obtain "satisfactory" middle ear (and , presumably, sinus) killing, one needs a ratio of 3:4 , providing a satisfactory diffusion into the respiratory epithelium/secretions, and perhaps killing rates in exce ss of75 %. Importantly, 100% killing is not achieved until one reaches ratio s of 8: 10. The pleasant surprise has been that all three types of data support the same conclusions about efficacy. Therefore, the convergence of data give s us better answers than we have had to date , but leaves us with surprisingly few effective (as measured by rea l ability to kill organisms) therapeutic choices. Several points made in the supplement include mentions of current laboratory breakpoints for defining resistance being set high enough that while the organi sm is reported as being susceptible to the antimicrobial in question, the levels in the ear and sinuses fail to reach the breakpoints.' In this setting, we see clinical failures even though the lab reports the organism as being susceptible. This is pertinent to virtually every oral beta-Iactam and H. influen zae. The picture is somewhat more difficult for pneumococcus, but we can assume that penicillin intermediate strain s will respond inconsistently to most oral beta-Iactams, and resistant strains will frequently persist in the face of related agents . Not surprisingly, ongoing efforts to adjust the breakpoints to correlate with achievable middle ear levels are vigoro usly opposed by many of the pharmaceutical companies, which would see big increases in the reported resistance rate s to their agents (and in collateral damage to their marketing efforts).
Resistance in Streptococcus Pneumoniae
This Journal carried the first warning about drug -resistant Streptococcu s pneumoniae (DRSP) in the ENT literature , and the mes sage was probably the first to accurately predict the magnitude of the problem in developed countries.' The current degree of resistance is much higher and much more important than most oto laryngologists realize. For most of North, Central and South America, Asia , and southern Europe, pneumococcal resistance is now the norm , with more than 50 % of all isolates no longer susceptible to beta-Iactams , and most of the se resistant to other classes of agents. (This , according to Centers for Disease Contro l (CDC) data presented at the Drug Resistant Streptococcus Pneumoniae Working Group-Otitis Media, 1997.) Of note is that the U.S. Pacific Northwest may have a somewhat lower rate. Worse still, in the types of patients typically see n in ENT practices (young age, winter month s, lots of antibiotic use, and failed therapy) the pneumococcal resistance rates are probabl y closer to 90% than to 50 %. Finally, in this type of population, the degree of resistan ce is also much hig her than the interm ediate range discussed in this supplement. Most of "our" non-susceptible pneumococci have MIC s that are either in the full resistant range, or at the upp er end (MIC > 0.5 mcg/ml) of the intermediate range, where killin g by relatively potent anti-pneumo coc cal agents (such as amoxicillin or cefuroxime axetil) is not con sistent.
As a snapshot: Of the 22 pneumococc al (ear and nasopharynx) isolates (January-Marc h 1998) from my Houston pediatric patients, only two were susceptible to penicillin. Fouteen of the isolates had high-intermediate or full penicillin resistance and full resistance to macrolide s and sulfa drugs. Therefore, the most common pneumococcal isolate in my patients is at least somewhat resistant to all commonly used classes of oral antibiotics. There is no reason to suspect that these findings are unique to Texas.' While much of the literature' s discussions have focused on the lactams' decl ining activity against pneumococci, that is only part of the story. An important point is that pneumococc al beta -lactam resistance is a relative issue-" that is, the organisms can be thought of as being "betalactam challenged" (credit to Michael Jacob s for the term). If we can give enough lactam, or if the tissue penetration and concentration are relatively good (as in the plasma and lung ), an MIC in the single digit range can be exceeded . It is a critic al issue; even though we may fail to cure the otitis media due to fully resistant pneumococci with some of our better oral agents (as above), the serum levels will be adequ ate to prevent bacteremia and most systemic suppurative compli cations. On the other hand , the MICs associated with some of the seco nd-generation cephalos porins (cefaclor and loracarbef), third-generation ceph alosporins (cefix ime, ceftibuten), macrolides (azithromycin, clari thromycin) and sulfas are high enough that we cannot achieve those levels in any extrace llular co mpart ment, and the patient becomes at risk for becoming "bad sick" in the face of such thera py. ' Macrolide resistance has skyrocketed in many (if not most) of the world, and now exceeds beta-Iactam resistance in terms ofoverall prevalence, in some popul ations. In the case of azithrom ycin, the prolonged tissue levels of which allow for some uniqu e dosing paramete rs, the same charac teristics seem to impress ively select for carriage of macrolide-resistant pneum ococci -for month s after a single course of therapy.' Furth er , if our pneum ococc al infection has demon strated resistance to betalactam s, most (perhaps 70 %) are also resi stant to macrolid es and/or sulfas . Again, although macrol idesusceptible pneumococci are rapidly eliminated with azithromycin and clarithromycin, the macrolide-resistant strains are typically highly resistant.
Hemophilus Influenzae Failures
Hemophilu s is an important orga nism in pedi atric otolaryngology. For years it has been the organism most commonly isolated from mucoid and serous middle ear effusions, and it is traditionally difficult to clear from the virally dama ged mucosa that charac terizes the respiratory tract of the typical otiti s-pron e child. The double tap studies of Dagan and others have clarified the source of our traditional insecurities about a number of agents that have been said to "work" in otiti s media. That is, the natur al resolution rate s, at least in isolated (not previously treated) otitis med ia, when the outcome was assessed at 10-14 days, was high enough that an inac tive drug appeared to "work." Th at has been the case for H. infl uenzae acute otitis media (AOM) . However, it is my contention that the problem cases -defined as treatment failure s or otitis-pro ne patient s-do not respond as consistently to placebo. The doubl e-t ap studies, with the second tap at three to five days into therapy, sort through all ofthis. The age nts that might not be measurably more acti ve than placebo against H. infl uenzae include cefaclor, loracarbef, cefproz il, azithromyc in and clarith romy cin -a conclusion reached by looking at ava ilable doubl e-t ap studies" and exam ining MIC s versus tissue (extrace llular) concentrations. Given that pre viously-treated children with persistent or intercurrent AOM are likely to harbor DRSP and/or H. influenzae, the abov e agents are particularly poor choic es for second-line ther apy -since they are unlik ely to be active again st either. Even for first-line therapy , it is doubtful that those agents have greater ove rall efficacy or safety (from inva sive infections) than amoxicillin, particularly if the amoxicillin is dosed at the higher ranges alluded to in the supplement.
In 1997, the CDC con vened their DRSP therapeu tic working group, and invited a number of otitis media "opinion leaders" to develop some guidelines on otitis media treatment in today's era of DRSP. These have been put together in a manuscript (Dowe ll S, et ai, submitted for publ ication), and an abstracted version will likely be released to all pertinent specia lty journ als and bulletin s. The recommend ations: First-line therapy for AOM should still be amoxicillin (+/-clavulanate) -but dosed at 60-90 mg/kg/d (most of us favor the higher range). The rationale:
We really want to treat the pneumococci, and most pneumococci that cause AOM are no longer consistently eliminated with conventional dosing ranges . These doses are also supported by the most recent pharmacokinetic data.'
For seco nd-line therapy, the only two agents felt to come close to amoxicillin' s efficacy against pneumococcus-and to be better against H. influ enzae (including
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A unique but cheap ENT system, which combines the handpieces with a wide range of sucker end instruments. Aspirating myringotome GUEST EDITORIAL beta-lactamase-producing strains)-were amoxicillinclavulanate and cefuroxime axetil. Cefpodox ime proxetil might also be included as second-line therapy; it is somewhat less active again st pneumococci (due to reduced bioavailability) than the other two, but proportionately more active against Hemophilus.
Those recomm endations still fall short on optim al efficacy for the kind of pneumococci most commonly encountered in our practice. If those agents fail, we have only three reasonable (empiric) choices: several days of ceftriaxone (one shot will probably not be consistently active against DRSP); clindamycin (resistance is rising but is still fairly low, and most of the time we would want to add drugs with gram-negative activity , i.e., TMP-SMX, ceftibuten, cefixime); or amoxicillin -clavulanate with additional amoxicillin (taking the amoxicillin component to 80-90 mg/kg/d) . Even those combinations will fail with some infections due to resistant pneumococci, especially as the MICs continue their upward march to exceed the amount of drug being presented to the organism in the respiratory tract.
In summary, DRSP is a real and a serious problem, and H. influenzae failure s are costly and irritating. How much of a problem? By my estimate, perhaps 20-50% of the otitis-prone children currently referred to otolaryngologists have been so catego rized becau se of poor respon se to antimicrobials -usually several times over. While some do have true eustachi an tube dysfunction or immunod eficiencies that make them good candid ates for tubes, many of these children could be more effectively treated if clinicians used better judgment in their choice of empirically selected agents , or if the clinicians had specific culture and sensitivity data from tympanocentesis or (perhaps) nasopharyngeal cultures -and knew how to interpret those data . No doubt about it: We face major challenges, and things will worsen before they improve.
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